Interleukin-31 and Pruritic Skin

Skin inflammation often evokes pruritus, which is the major subjective symptom in many inflammatory skin diseases such as atopic dermatitis and prurigo nodularis. Pruritus or itch is a specific sensation found only in the skin. Recent studies have stressed the pivotal role played by interleukin-31 (IL-31) in the sensation of pruritus. IL-31 is produced by various cells including T helper 2 cells, macrophages, dendritic cells and eosinophils. IL-31 signals via a heterodimeric receptor composed of IL-31 receptor A (IL-31RA) and oncostatin M receptor β. Recent clinical trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis. The IL-31 pathway and pruritic skin are highlighted in this review article.

[1]  J. Paolini,et al.  Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta , 2021, Experimental dermatology.

[2]  C. Foocharoen,et al.  Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms , 2020, Heliyon.

[3]  M. Obeidat,et al.  Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. , 2020, Cytokine.

[4]  S. Kwatra,et al.  Health-related quality of life and economic burden of chronic pruritus. , 2020, The Journal of investigative dermatology.

[5]  M. Hoon,et al.  The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching , 2020, Immunity.

[6]  M. Kawashima,et al.  Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. , 2020, The New England journal of medicine.

[7]  T. Akiyama,et al.  New insights into the mechanisms behind mechanical itch , 2020, Experimental dermatology.

[8]  K. Sawanyawisuth,et al.  Interleukin-31 and Chronic Pruritus of Unknown Origin , 2020, Biomarker insights.

[9]  B. Wang,et al.  Inhibition of mite‐induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan , 2020, Allergy.

[10]  S. Feldman,et al.  New and Emerging Systemic Treatments for Atopic Dermatitis , 2020, Drugs.

[11]  Brian S. Kim,et al.  New and Emerging Treatments for Inflammatory Itch. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  Liang Han,et al.  Visualizing the itch-sensing skin arbors , 2020, bioRxiv.

[13]  T. Bieber,et al.  Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. , 2020, The New England journal of medicine.

[14]  T. Hashimoto,et al.  Pathophysiological mechanisms of itch in bullous pemphigoid. , 2020, Journal of the American Academy of Dermatology.

[15]  T. Hashimoto,et al.  Mechanisms of itch in stasis dermatitis: Significant role of IL-31 from macrophages. , 2020, The Journal of investigative dermatology.

[16]  M. Steinhoff,et al.  Interleukin‐4 and interleukin‐13 evoke scratching behaviour in mice , 2019, Experimental dermatology.

[17]  M. Furue,et al.  Selective role of neurokinin B in IL-31-induced itch response in mice. , 2019, The Journal of allergy and clinical immunology.

[18]  S. Garg,et al.  Alterations in circulating concentrations of IL-17, IL-31 and total IgE in dogs with atopic dermatitis. , 2019, Veterinary dermatology.

[19]  M. Furue,et al.  IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis , 2019, International journal of molecular sciences.

[20]  M. Szczepanik,et al.  The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis. , 2019, Veterinary dermatology.

[21]  M. Furue,et al.  Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study , 2019, The Journal of dermatology.

[22]  T. Hashimoto,et al.  Pruritus in ordinary scabies: IL‐31 from macrophages induced by overexpression of thymic stromal lymphopoietin and periostin , 2019, Allergy.

[23]  T. Olivry,et al.  Proactive maintenance therapy of canine atopic dermatitis with the anti‐IL‐31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares? , 2019, Veterinary dermatology.

[24]  J. Silverberg,et al.  Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. , 2019, The Journal of allergy and clinical immunology.

[25]  M. Furue,et al.  Nemolizumab in patients with moderate‐to‐severe atopic dermatitis: Randomized, phase II, long‐term extension study , 2018, The Journal of allergy and clinical immunology.

[26]  M. Furue,et al.  Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis , 2018, Allergy.

[27]  Tsukasa Suzuki,et al.  Cynomolgus monkey model of interleukin‐31‐induced scratching depicts blockade of human interleukin‐31 receptor A by a humanized monoclonal antibody , 2018, Experimental dermatology.

[28]  H. Moyaert,et al.  A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client‐owned dogs with atopic dermatitis , 2017, Veterinary dermatology.

[29]  Jonathan R. Brestoff,et al.  Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.

[30]  S. Gangemi,et al.  Interleukin 31 is involved in intrahepatic cholestasis of pregnancy , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[31]  M. Furue,et al.  Itch in Atopic Dermatitis. , 2017, Immunology and allergy clinics of North America.

[32]  M. Furue,et al.  The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction , 2017, Nature Communications.

[33]  S. Dillon,et al.  Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL‐31 neutralizing antibody , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[34]  T. Ruzicka,et al.  Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. , 2017, The New England journal of medicine.

[35]  S. Dunham,et al.  A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. , 2016, Veterinary dermatology.

[36]  A. Jegga,et al.  IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function , 2016, PloS one.

[37]  J. Kere,et al.  The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. , 2016, The Journal of allergy and clinical immunology.

[38]  A. Kim,et al.  Control of the Physical and Antimicrobial Skin Barrier by an IL-31–IL-1 Signaling Network , 2016, The Journal of Immunology.

[39]  J. Guitart,et al.  Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. , 2016, Acta dermato-venereologica.

[40]  H. Nakagawa,et al.  The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study , 2016, The British journal of dermatology.

[41]  R. Mccall,et al.  IL‐31‐induced pruritus in dogs: a novel experimental model to evaluate anti‐pruritic effects of canine therapeutics , 2015, Veterinary dermatology.

[42]  E. Carstens,et al.  Central Mechanisms of Itch. , 2016, Current problems in dermatology.

[43]  M. Furue,et al.  New therapies for controlling atopic itch , 2015, The Journal of dermatology.

[44]  A. Duschl,et al.  Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3)* , 2015, The Journal of Biological Chemistry.

[45]  R. Kakigi,et al.  Itch and brain , 2015, The Journal of dermatology.

[46]  S. Akira,et al.  STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch , 2015, Nature Medicine.

[47]  DengYong,et al.  Elevated TGF-β1/IL-31 Pathway Is Associated with the Disease Severity of Hepatitis B Virus–Related Liver Cirrhosis , 2015 .

[48]  G. Yosipovitch,et al.  Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. , 2015, Clinical immunology.

[49]  A. Jegga,et al.  Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression* , 2015, The Journal of Biological Chemistry.

[50]  M. Sokołowska-Wojdyło,et al.  Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. , 2015, Acta dermato-venereologica.

[51]  S. Jee,et al.  Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. , 2014, Journal of the American Academy of Dermatology.

[52]  P. Nibbering,et al.  Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[53]  N. Yamashita,et al.  Anti‐IL‐31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice , 2014, British journal of pharmacology.

[54]  D. Ribatti,et al.  The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma , 2014, Leukemia.

[55]  D. Werner,et al.  Human Th2 but Not Th9 Cells Release IL-31 in a STAT6/NF-κB–Dependent Way , 2014, The Journal of Immunology.

[56]  A. Morita,et al.  Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. , 2014, Journal of dermatological science.

[57]  T. Buhl,et al.  A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. , 2014, The Journal of allergy and clinical immunology.

[58]  M. Hoon,et al.  Why we scratch an itch: the molecules, cells and circuits of itch , 2014, Nature Neuroscience.

[59]  M. Maurer,et al.  Interleukin‐31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge , 2014, Allergy.

[60]  S. Hubchak,et al.  Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. , 2013, American journal of physiology. Renal physiology.

[61]  E. Carstens,et al.  Neural processing of itch , 2013, Neuroscience.

[62]  J. Bonaventura,et al.  Hemoglobin-induced endothelial cell permeability is controlled, in part, via a myeloid differentiation primary response gene-88-dependent signaling mechanism. , 2013, American journal of respiratory cell and molecular biology.

[63]  S. Durham,et al.  Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. , 2013, The Journal of allergy and clinical immunology.

[64]  K. Sayama,et al.  Eccrine Sweat Contains IL-1α, IL-1β and IL-31 and Activates Epidermal Keratinocytes as a Danger Signal , 2013, PloS one.

[65]  J. Collins,et al.  Transcription Factors Sp1 and Hif2α Mediate Induction of the Copper-transporting ATPase (Atp7a) Gene in Intestinal Epithelial Cells during Hypoxia* , 2013, The Journal of Biological Chemistry.

[66]  T. Werfel,et al.  Interleukin (IL)‐31 activates signal transducer and activator of transcription (STAT)‐1, STAT‐5 and extracellular signal‐regulated kinase 1/2 and down‐regulates IL‐12p40 production in activated human macrophages , 2013, Allergy.

[67]  R. Mccall,et al.  Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. , 2013, Veterinary dermatology.

[68]  S. Kežić,et al.  Increased frequencies of IL‐31‐producing T cells are found in chronic atopic dermatitis skin , 2012, Experimental dermatology.

[69]  R. Fölster-Holst,et al.  IL‐31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[70]  Y. Tada,et al.  Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. , 2012, Acta dermato-venereologica.

[71]  Y. Miyagi,et al.  HIF2α-Sp1 interaction mediates a deacetylation-dependent FVII-gene activation under hypoxic conditions in ovarian cancer cells , 2012, Nucleic acids research.

[72]  B. Lüscher,et al.  IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. , 2012, The Journal of allergy and clinical immunology.

[73]  L. French,et al.  IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. , 2012, Acta dermato-venereologica.

[74]  A. Kim,et al.  Ultraviolet B radiation and reactive oxygen species modulate interleukin‐31 expression in T lymphocytes, monocytes and dendritic cells , 2011, The British journal of dermatology.

[75]  A. Heratizadeh,et al.  Staphylococcal α-Toxin Induces a Higher T Cell Proliferation and Interleukin-31 in Atopic Dermatitis , 2011, International Archives of Allergy and Immunology.

[76]  T. Werfel,et al.  Functional effects of interleukin 31 in human primary keratinocytes , 2011, Allergy.

[77]  Riitta Lahesmaa,et al.  Genomic views of STAT function in CD4+ T helper cell differentiation , 2011, Nature Reviews Immunology.

[78]  MHM Ezzat,et al.  Serum measurement of interleukin‐31 (IL‐31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[79]  M. Furue,et al.  Collared mice: a model to assess the effects of scratching. , 2010, Journal of dermatological science.

[80]  K. Matsushima,et al.  Anti‐interleukin‐31‐antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis , 2009, Experimental dermatology.

[81]  M. Steinhoff,et al.  IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[82]  B. Harder,et al.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[83]  Scott R. Presnell,et al.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice , 2004, Nature Immunology.

[84]  R. McIntyre,et al.  Toll-like receptor-4 signaling mediates pulmonary neutrophil sequestration in response to gram-positive bacterial enterotoxin. , 2002, The Journal of surgical research.